Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA accepts for filing diquafosol NDA for dry eye

Sep. 15, 2003

EntreMed grants Oxford BioMedica gene rights for ophthalmic applications

Sep. 12, 2003

Good efficacy and safety profile described for ranibizumab in AMD

Sep. 3, 2003

Intravitreous hyaluronidase effective in reducing vitreous hemorrhage density

Sep. 3, 2003

VEGF Trap prevents blinding blood vessel growth in mice

Aug. 28, 2003

Improved vision in extension phase of Lucentis wet AMD study

Aug. 27, 2003

Priority review for Vitrase NDA

Aug. 25, 2003

Long-term efficacy of Retaane demonstrated in 24-month wet AMD trial

Aug. 25, 2003

New phase III trial of loteprednol etabonate for allergic rhinitis

Aug. 21, 2003

Selective iNOS inhibitors show potential in the treatment of endotoxin-induced uveitis

Aug. 21, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.